Peel Hunt Limited Reiterates McBride (MCBRF) Buy Recommendation

Peel Hunt reiterated a Buy on McBride (OTCPK:MCBRF); the analyst consensus one‑year price target averages $2.20 (range $2.08–$2.38), though Fintel flags an anomalous “infinite” upside figure tied to a reported $0.00 closing price. Company projections show annual revenue of $709m, down about 23.5%, and a projected non‑GAAP EPS of -$0.13, underscoring weak near‑term fundamentals. Institutional interest is modest but steady—19 funds hold roughly 2.461m shares (up 0.41%) with average portfolio weight ~0.01% (up ~17%)—suggesting limited but persistent investor positioning despite the deterioration in top‑line and profitability metrics.

Analysis

Fintel reports that Peel Hunt reiterated coverage of McBride (OTCPK:MCBRF) with a Buy on November 20, 2025, and the analyst consensus one‑year price target averages $2.20 (range $2.08–$2.38) as of November 20, 2024; Fintel also flags an anomalous “infinite” upside figure tied to a reported closing price of $0.00. The broker target band implies upside versus the cited price datum, but the $0.00 close and infinity metric reflect a data/reporting anomaly rather than a conventional valuation signal.

Company fundamentals in the report show projected annual revenue of $709m, down 23.49% year‑over‑year, and a projected non‑GAAP EPS of -$0.13, indicating a materially weakened near‑term top line and continued unprofitability. Institutional positioning is modest but stable: 19 funds hold roughly 2.461m shares (up 0.41%) with average portfolio weight of 0.01% (up 16.97%), and DFA entities account for the largest disclosed stakes (e.g., 977k shares reported).

Fintel’s sentiment and market‑impact signals are neutral-to‑low (sentiment_label "mixed", market_impact_score 0.12), which, together with small institutional weight and weak fundamentals, suggests limited immediate market momentum from the report. The juxtaposition of a Buy rating and modest price targets against declining revenue and negative EPS highlights execution and recovery risk; investors should prioritize verification of market data and near‑term operating metrics before increasing exposure.

Key Decisions for Investors

• Verify the quoted closing price and analyst upside calculation before acting given the reported $0.00 close and anomalous infinite upside figure, don't base valuation decisions on that metric
• Given the projected 23.5% revenue decline and non‑GAAP EPS of -$0.13, maintain a cautious or underweight stance until the company reports stabilization in revenue and a return toward profitability
• If initiating or maintaining exposure, size positions conservatively, monitor quarterly revenue/EPS trends and subsequent institutional 13F filings for shifts in allocation, and consider hedging or tight risk limits due to low market impact and potential liquidity constraints